S 2351
110th Congress
Senate
Taxation
Antibiotics
Commerce
Communicable diseases
Drug industry
Health
Income tax
Medical tests
Pharmaceutical research
Preventive medicine
Research and development tax credit
Science, Technology, Communications
Vaccines
Virus diseases
A bill to amend the Internal Revenue Code of 1986 to provide a tax credit for medical research related to developing qualified infectious disease products.
Introduced: November 14, 2007
Introduced by:
Schumer, Charles E.
Democratic
· New York
See on congress.gov
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 14, 2007
Read twice and referred to the Committee on Finance.
Nov 14, 2007
Introduced in Senate
Plain-English summary
Amends the Internal Revenue Code to allow a general business tax credit for 50% of expenses paid for research and development of any qualified infectious disease product. Defines "qualified infectious disease product" as any antibiotic drug, antiviral, diagnostic test, biological product, or vaccine developed to treat, detect, prevent, or identify certain pathogens. Terminates such credit after 2012.
What's happening now
Read twice and referred to the Committee on Finance.
Committees of jurisdiction
1